PMU-Autor/inn/en
Harrer AndreaAbstract
Stroke still remains a major healthcare problem. The growing understanding of the mechanism of cell death in ischemia leads to new approaches in stroke treatment. The aim of neuroprotection is to reduce the post-stroke impairment and the overall costs that are accompanied in patients with severe disability. Despite encouraging data from experimental animal models, almost all neuroprotective therapies have, to date, not been established in clinical routine. In this part B of our review on stroke therapies we provide an overview on future candidates in stroke therapy and neuroprotective agents that are under investigation.
Useful keywords (using NLM MeSH Indexing)
Animals
Brain Ischemia/complications
Brain Ischemia/drug therapy*
Clinical Trials as Topic
Drug Evaluation, Preclinical
Drug Therapy, Combination
Drugs, Investigational/administration*
dosage
Drugs, Investigational/adverse effects
Drugs, Investigational/therapeutic use*
Humans
Intracranial Thrombosis/prevention*
control
Neuroprotective Agents/administration*
dosage
Neuroprotective Agents/adverse effects
Neuroprotective Agents/therapeutic use*
Stroke/drug therapy*
Stroke/etiology
Treatment Outcome